about
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodiesAdvances in the treatment of relapsed or refractory Hodgkin's lymphomaBrentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma.The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).Hodgkin's lymphoma therapy: past, present, and future.Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies.Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.Intracellular delivery and trafficking dynamics of a lymphoma-targeting antibody-polymer conjugate.Targeting macrophages in classical Hodgkin's lymphoma may seem rational, but is it safe?Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.Immunoconjugates and long circulating systems: origins, current state of the art and future directionsTargeted therapy in rare cancers--adopting the orphans.The current status and future impact of targeted therapies in non-Hodgkin lymphoma.CD30 as a therapeutic target for lymphoma.Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients.Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia.Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases.Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia.Pathobiology of hodgkin lymphomaAn Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia
P2860
Q21131216-14B0515D-F837-48D3-AEAA-C7720796D86AQ27694504-CA6661E9-D1E7-440D-ABC4-29B9CB5736A2Q33410081-6534F7A7-9213-4FC6-AF69-D2F16EC61705Q33877409-5B04D731-42E2-4FEA-ABFB-BEBFA19C8578Q34296914-D7AEB526-DA25-4B43-A40F-4E78E1FA70E9Q34557179-2B271CEF-D72F-4F99-99C7-95CDE1828D09Q35223780-13A1F708-2F4E-4FE9-B108-B7F87DFC90EDQ36692593-3FE03F0C-A97E-4D6C-8788-1960D656E2CEQ37830204-5E389BD7-4C2D-4B2D-9D59-0F8F6A869EB7Q37991128-69FC892F-C6AB-48C5-9B3A-0B7D46CB4514Q38042256-670C79CA-2247-4E1F-AE4E-0F51612D6405Q38042324-18EE6191-F676-485A-9033-89A03C9C65A4Q38095123-38CC8CC5-8E02-4F66-8E8E-465345E9A26FQ38138482-CD206E81-80E0-4F0F-B55F-9B5A4DB25667Q39185522-FDCF2F7D-3839-4DF8-B4FC-10982AF969E2Q39591125-EE7F816D-CC04-40F2-96C8-A680DBF7F4EDQ39600333-7E38A289-BF4F-4E95-9FCF-BE1DE6892603Q48150809-6C55ECCD-C882-450F-BA2A-ED6B0FC91E42Q50970909-4D68ECB4-C38A-45C2-A0BE-59E401760EE3Q56986903-86879CA2-0540-49DB-A951-28221D7D11EFQ57257115-28DCA259-20D0-46EA-82FD-8E5ABBABBF60
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-CD30 Antibodies for Hodgkin lymphoma.
@en
Anti-CD30 Antibodies for Hodgkin lymphoma.
@nl
type
label
Anti-CD30 Antibodies for Hodgkin lymphoma.
@en
Anti-CD30 Antibodies for Hodgkin lymphoma.
@nl
prefLabel
Anti-CD30 Antibodies for Hodgkin lymphoma.
@en
Anti-CD30 Antibodies for Hodgkin lymphoma.
@nl
P1476
Anti-CD30 Antibodies for Hodgkin lymphoma
@en
P2093
Kelley V Foyil
P2888
P304
P356
10.1007/S11899-010-0053-Y
P577
2010-07-01T00:00:00Z